Inclusion Criteria:~* Diagnosis of mild to moderate AD~* Clinical laboratory values within normal range or <
1.5 times ULN~* Life expectancy of >2 years~* Able and willing to provide written informed consent~* Must have
participated in all study activities of SPG302-ALZ-101, the parent study~
